Craft
Navigen

Navigen

Total Funding

$1.7 M

Navigen Summary

Company summary

Overview
Navigen is a pharmaceutical discovery company focusing on D-peptides. It is engaged in the development of CPT31, a compound designed to treat and prevent HIV. In addition, the company develops a D-peptide for cancer immunotherapy that targets SIRPα, an innate checkpoint inhibitor.
Type
Private
Status
Active
Founded
2006
HQ
Salt Lake City, UT, US | view all locations
Website
http://www.navigenpharma.com/
Cybersecurity rating
Sectors

Key people

  • Alan Mueller

    Alan Mueller, Vice President of Research

  • Hunter Jackson

    Hunter Jackson, CEO and Chairman

LocationsView all

2 locations detected

  • Salt Lake City, UT HQ

    United States

    675 Arapeen Dr #103

  • Salt Lake City, UT

    United States

    383 Colorow Dr

Footer menu